Topical Immunotherapy with Diphencyprone for in Transit and Cutaneously Metastatic Melanoma

Topical diphencyprone (DPCP) can be used to treat in transit and cutaneously metastastatic melanoma. To date, 50 patients have received DPCP therapy for at least 1 month at our institution, with complete clearance of cutaneous disease in 46% and partial response in a further 38% of patients. Topical immunotherapy with DPCP is inexpensive and well-tolerated and should be considered in patients with skin metastases unsuitable for or refractory to other forms of therapy. J. Surg. Oncol. 2014 109:308-313. (c) 2013 Wiley Periodicals, Inc.